Plasmapheresis in Management of Oral Autoimmune Disorders

  • Kanupriya Gupta MDS- Oral Pathology, Ph.D Research Scholar & Senior Research Fellow, Division of Oral Pathology, Faculty of Dental Sciences, IMS, BHU, Varanasi, India

Abstract

Systemic autoimmune diseases based on an immune pathogenesis produce autoantibodies and circulating immune complexes, which cause inflammation in the tissues of various organs. In most cases, these diseases have a bad prognosis without treatment. Autoimmune disorders are a group of poorly understood diseases in which the body fails to distinguish between self and non- self which could result in damage to the self. Oral mucous membrane may be affected by a variety of autoimmune mucocutaneous diseases such as pemphigus, bullous pemphigoid, mucous membrane pemphigoid, lichen planus, erythema multiforme, Steven Johnson syndrome, epidermolysis bullosa, linear IgA disease etc. These diseases (commonest being pemphigus) cannot be controlled in some cases, even with very high doses of systemic corticosteroids and immunosuppressive agents. In such cases plasmapheresis is one of the most effective therapeutic methods to deplete sera of immunoglobulin, including pathogenic autoantibodies. The aim of this review is to describe plasmapheresis as an adjunct therapy for oral autoimmune disorders.


Keywords: autoimmune diseases, plasmapheresis, pemphigus, lichen planus, erythema multiforme, Steven Johnson syndrome, epidermolysis bullosa, linear IgA disease

Downloads

Download data is not yet available.

Author Biography

Kanupriya Gupta, MDS- Oral Pathology, Ph.D Research Scholar & Senior Research Fellow, Division of Oral Pathology, Faculty of Dental Sciences, IMS, BHU, Varanasi, India

MDS- Oral Pathology, Ph.D Research Scholar & Senior Research Fellow, Division of Oral Pathology, Faculty of Dental Sciences, IMS, BHU, Varanasi, India

References

1. Helen iE, iKambic, iYukihiko iNosk iet ial. iPlasmapheresis: iHistorical iPerspective, iTherapeutic iApplications, iand iNew iFrontiers. iArtificial iOrgans. i1993;17(10):850-881.
2. Wallace iDJ. iApheresis ifor ilupus ierythematosus. iLupus. i1999; i8(3):174-180.
3. Shumark iKH, iRock iGA. iTherapeutic iplasma iexchange. iN iEngl iJ iMed. i1984; 310:762- i71.
4. Tesar iV, iJelinkova iE, iMasek iZ, iet ial. iInfluence iof iplasma iexchange ion iserum ilevels iof icytokines iand iadhesion imolecules iin iANCA ipositive irenal ivasculitis. iBlood iPurif. i1998; 16(2):72-80.
5. Lockwood iCM, iWorlledge iS, iNicholas iA, iCotton iC, iPeters iDK. iReversal iof iimpaired isplenic ifunction iin ipatients iwith inephritis ior ivasculitis i(or iboth) iby iplasma iexchange. iN iEngl iJ iMed. i1979; 300(10):524- i30.
6. Low iA, iHotze iA, iKrapf iF, iSchranz iW, iManger iBJ, iMahlstedt iJ, iWolf iF, iKalden iJR. iThe inonspecific iclearance ifunction iof ithe ireticuloendothelial isystem iin ipatients iwith iimmune icomplex imediated idisease ibefore iand iafter itherapeutic iplasmapheresis. iRheumatol iInt. i1985; 5(2):69- i72.
7. Dau iPC. iIncreased iproliferation iof iblood imononuclear icells iafter iplasmapheresis itreatment iof ipatients iwith idemyelinating idisease. iJ iNeuroimmunol. i1990; 30(1):15-21.
8. Hanly iJG, iHong iC, iZayed iE, iJones iJV, iJones iE. iImmuno imodulating ieffects iof isynchronized iplasmapheresis iand iintravenous ibolus icyclophosphamide iin isystemic ilupus ierythematosus. iLupus. i1995; 4(6):457- i63.
9. Byrnes iJJ, iKhurana iM. iTreatment iof ithrombotic ithrombocytopenic ipurpura iwith iplasma. iN iEngl iJ iMed. i1977; 297:1386- i9.
10. Shumark iKH, iRock iGA. iTherapeutic iplasma iexchange. iN iEngl iJ iMed. i1984; 3(10):762- i71.
11. Bystryn iJC, iGraf iMW, iUhr iJW: iRegulation iof iantibody iformation iby iserum iantibody: iII. iRemoval iof ispecific iantibody iby imeans iof iexchange itransfusion. iJ iExp iMed. i1970; 132(6):1279-1287.
12. Bystryn iJC, iSchenkein iI, iUhr iJW: iA imodel ifor ithe iregulation iof iantibody isynthesis iby iserum iantibody. iProg iImmunol i1971; 1:627-636.
13. Roujeau iJC, iAndre iC, iJoneau iFabre iM, iLauret iP, iFlechet iML, iKalis iB, iRevuz iJ, iTouraine iR. iPlasma iexchange iin ipemphigus: iuncontrolled istudy iof iten ipatients. iArch iDermatol. i1983; 119(3):215-221.
14. Derksen iRH, iSchuurman iHJ, iGmelig-Meyling iFH, iStruyvenberg iA, iKater iL. iRebound iand iovershoot iafter iplasma iexchange iin ihumans. iJ iLab iClin iMed i1984; 104(1):35-43.
15. Terman iDS, iGrarcia-Rinaldi iR, iDanneman iB, iMoore iD, iCrumb iC, iTavel iA, iPoser iR. iSpecific isuppression iof iantibody irebound iafter iextracorporeal iimmunoadsorption: icomparison iof isingle iversus icombination ichemotherapeutic iagents. iClin iExp iImmunol. i1978; 34(1):32-41.
16. Di iGiacomo iA, iNorth iRJ. iT icell isuppressors iof iantitumor iimmunity. iThe iproduction iof iLy-1-, i2+ isuppressors iof idelayed isensitivity iprecedes ithe iproduction iof isuppressors iof iprotective iimmunity. iJ iExp iMed. i1986;164(4):1179-92.
17. Gagnon iRF, iMac iLennan iIC: iRegulation iof isecondary iantibody iresponse iin irodents. iPotentiation iof iIgG iproduction iby icyclophosphamide. iClin iExp iImmunol. i1979; 37(1):89-97.
18. Bystryn iJC. iPlasmapheresis itherapy iof ipemphigus. iArch iDermatology. i1988; 124(11):1702-1704.
19. Saydain iG, iGeorge iL, iRaoof iS. iNew itherapies: iplasmapheresis, iintravenous iimmunoglobulin, iand imonoclonal iantibodies. iCrit iCare iClin. i2002; 18(4):957-975.
Statistics
1 Views | 5 Downloads
How to Cite
Gupta, K. (2019). Plasmapheresis in Management of Oral Autoimmune Disorders. Journal of Drug Delivery and Therapeutics, 9(3), 658-660. https://doi.org/10.22270/jddt.v9i3.2905